top of page

Sven Kili, MD

Cell and Gene Therapy Commercialization Expert

Career Highlights

  • Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases; oversaw teams developing and commercializing gene therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo
    gene therapy to be approved for children with ADA-SCID, Wiskott - Aldrich syndrome (WAS), Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia

  • Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery; led the clinical development, approval and commercialization activities of the first combined ATMP product in the EU for MACI®. Prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US

  • Led the cell therapy activities and oversaw all UK and Irish regulatory functions and was the QPPV for pharmacovigilance for Geistlich Pharma

  • Board member of CCRM, co-chair of the ARM Gene Therapy Steering Committee and co-chair of the ISCT Business models & Investment committee

  • SAB Member for the LGC Group

  • Received an academic appointment as Chair at UCL for the course entitled “MSc in Manufacture and Commercialization of Stem Cell and Gene Therapies” where he leads the course steering committee.


  • MB, ChB; Stellenbosch University

  • MRCS; Royal College of Surgeons of England

bottom of page